What is it, and what do the rules allow?

What does the name mean?

BPC-157 is made in a lab from a short chain of protein parts.

The letters refer to “Body Protection Compound.”

It is made to resemble a piece of a protein reported by researchers in stomach juice. The product is made in a lab, rather than taken from stomach juice.

Is there an approved use?

The Food and Drug Administration (FDA) is the US medicine review agency.

As of September 2026, the FDA had approved no use for BPC-157 in the United States.

The FDA’s review also found no approved medicine containing it in any country.

That includes claims about tendons, joints and the gut; they are not approved uses.

Can a pharmacy simply make it to order?

Compounding means making a medicine to order, usually when ready-made medicine cannot meet a person’s needs.

As of September 2026, ordinary pharmacies cannot legally use BPC-157 as a raw ingredient in medicines made to order.

The law sets rules about which ingredients they may use. These are legal rules, not tests of a sample in a lab.

An ingredient needs to meet an official quality standard for use in medicine. If no such standard exists, the ingredient must already be part of an approved drug. If neither applies, it must be on the FDA’s list of permitted ingredients.

BPC-157 meets none of those requirements.

The FDA has a temporary policy for some ingredients still under review. It plans not to take legal action against pharmacies that use those ingredients, if they meet the policy’s conditions.

BPC-157 is not covered by that policy. The policy does not make an ingredient legal to use.

Having a prescription alone does not let a pharmacy use BPC-157.

Did a withdrawn request change that?

The FDA’s page lists BPC-157 as “nominated but withdrawn” and gives April 22, 2026 as its “current as of” date.

That means the groups asking for it to be considered took back their requests.

Taking back a request is not FDA permission to use BPC-157. The page still lists the FDA’s concerns about possible harm.

In July 2026, FDA staff recommended leaving BPC-157 off the list of ingredients ordinary pharmacies may use. That was a recommendation, not a final decision.

An advisory committee, a panel that gives the FDA advice, met in July 2026. The FDA had not published that panel’s vote by September 28, 2026.

Even a vote in favour would not change the pharmacy rules on its own.

The September 2026 rules described above still do not allow ordinary pharmacies to use BPC-157 as a raw ingredient.